1. Engineering IgG-like bispecific antibodies—an overview[J];Krah;Antibodies,2018
2. The evolution of bispecific antibodies[J];Gera;Exp. Opin. Biol. Ther.,2022
3. Mosunetuzumab: first approval[J];Kang;Drugs,2022
4. Faricimab: First Approval[J];Shirley;Drugs,2022
5. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma (accessed 03 November 2022).